Blogs
Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies
Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.
Videos and animations
PhysioMimix® cross-species DILI CRS for enhanced IVIVE
Gain clarity, confidence, speed, and enhance your ethical responsibility by leveraging our cross-species Drug-induced liver injury assays (human, rat and dog) in your drug discovery or development workflow. Improve your in vitro to in vivo extrapolation (IVIVE) capabilities today via our DILI Contract Research Service.
Blogs
CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI
Building Confidence in MPS for Regulatory Applications!
Brochures & Flyers

PhysioMimix Bioavailability assay kit: Human 18 brochure
Modernize your workflow with the only in vitro bioavailability assessment tool on the market. Elevate your workflow with our all-in-one Bioavailability assay kit containing everything you need to recreate our human in vitro Gut/Liver-on-a-chip model and Bioavailability assay in your laboratory.
Brochures & Flyers
PhysioMimix DILI assay kit: Human 24 brochure
Predict more complex, latent and immune-related hepatotoxicity in vitro. The PhysioMimix DILI assay kit contains everything you need to recreate our FDA-recognized assay in your own laboratory.
Webinars
Harnessing Liver-on-a-chip models for drug safety
Webinar Series 8 Episode 2
Discover how to leverage human and animal Liver-on-a-chip (aka Liver microphysiological systems) in toxicology studies to enhance data translatability between preclinical testing and clinical applications.
Featuring industry experts from CN Bio and Bristol Myers Squibb.
Blogs
Why the FDA animal testing phase-out for monoclonal antibodies?
In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal antibodies, followed by other drugs – signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing.
Blogs
Microphysiological systems for mAbs development: how do they address animal limitations?
Part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs).
Articles
How OOC can improve in vitro to in vivo translatability of preclinical data
Articles
Organ-on-a-chip: a modernized toolbox for drug discovery challenges
Transforming drug discovery with a modernised toolbox. OOC is transforming accuracy, reducing failures, and accelerating new therapies.
Videos and animations
PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling
Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.
Videos and animations
PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights
Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development